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Abstract  
Ovarian cancer is the most deadly gynecological cancer and unlike most other 
neoplasms, survival rates for ovarian cancer have not significantly improved in recent 
decades. We show that RAD6, an ubiquitin conjugating enzyme is significantly 
overexpressed in ovarian tumors and its expression increases in response to 
carboplatin chemotherapy. RAD6 expression correlated strongly with acquired 
chemoresistance and malignant behavior of OC cells, expression of stem cell genes 
and poor prognosis of OC patients suggesting an important role for RAD6 in ovarian 
tumor progression. Upregulated RAD6 enhances DNA damage tolerance and repair 
efficiency of OC cells and promotes their survival. Increased RAD6 levels cause H2B 
ubiquitination-mediated epigenetic changes that stimulate transcription of stem cell 
genes, including ALDH1A1 and SOX2, leading to a cancer stem cell phenotype, which 
is implicated in disease recurrence and metastasis. Downregulation of RAD6 or its 
inhibition using a small molecule inhibitor attenuated DNA repair signaling and 
expression of CSC markers and sensitized chemoresistant OC cells to carboplatin. 
Together, these results suggest that RAD6 could be a therapeutic target to prevent and 
treat acquired chemoresistance and disease recurrence in OC and enhance the efficacy 
of standard chemotherapy. 
Introduction 
Ovarian cancer (OC) is often diagnosed at advanced stages with widespread intra-
abdominal disease or distant metastasis due to its insidious development. Although 
most OC patients respond well to initial surgical debulking and platinum-based 
chemotherapy, a significant percent of patients present with recurrent disease (reported 
rates ranging from 65-80%)1, and these recurrent tumors are frequently resistant to front 
line chemotherapeutic drugs thus making it the most deadly gynecological cancer2,3. It 
is believed that recurrent tumors are largely due to a small population of cancer cells 
that dedifferentiated as cancer stem cells (CSC) or tumor initiating cells. CSCs have 
properties, such as quiescence, enhanced DNA damage tolerance, increased multidrug 
efflux pumps, and anti-apoptotic signaling to evade treatment4–6. Moreover, CSCs are 
capable of proliferating, differentiating back into tumor cells and reestablishing tumors 
once treatment is concluded4. Thus, signaling mechanisms that promote acquired 
chemoresistance and CSC phenotype have been investigated as therapeutic targets to 
prevent and treat disease recurrence.   
RAD6 is an ubiquitin conjugating enzyme that was originally identified as a DNA repair 
protein in yeast and is highly conserved in all eukaryotes7. Humans have two RAD6 
genes (RAD6A and RAD6B also known as UBE2A and UBE2B) that have many 
overlapping functions, and both complement mutant RAD6 of Saccharomyces 
cerevisiae in DNA repair8. RAD6, in association with RAD18, regulates mutagenic DNA 
damage tolerance (DDT; translesion synthesis or TLS) and Fanconi anemia (FA) DNA 
repair pathways in response to various genomic insults, including chemo and radiation 
therapy9. Additionally, RAD6 regulates gene transcription in association with RNF20/40 
ubiquitin ligase by histone 2B (H2B) ubiquitination-mediated chromatin modifications10–
12. RAD6 is overexpressed in melanoma and breast cancer where it correlates with 
tumor development, progression and metastasis13–15. Our recent studies showed 
increased expression of RAD6 in ovarian tumors and its levels correlated with 
progressive disease16. In OC cell lines, RAD6 expression promoted development of a 
stem cell-like phenotype and resistance to carboplatin16. In this report we show that 
RAD6 promotes acquired chemoresistance in OC by stimulating monoubiquitination of 
FANCD2 and PCNA, proteins that are important for platinum drugs-induced DNA 
crosslink repair and DDT mechanisms, respectively17–21. Similarly, RAD6 is upregulated 
in response to chemotherapy and significantly correlated with expression of OC stem 
cell signaling genes ALDH1A1 and SOX2 and poor prognosis of OC patients. 
Additionally, RAD6 downregulation or inhibition using a small molecule inhibitor 
attenuated DNA repair signaling, expression of CSC markers and sensitized 
chemoresistant OC cells to carboplatin. Collectively, these results demonstrate that 
RAD6 could be a therapeutic target to prevent and treat acquired chemoresistance and 
disease recurrence in OC and enhance the efficacy of standard chemotherapeutic 
drugs in OC patients. 
Results 
RAD6 promotes CSC gene expression and is necessary for proper DNA damage 
response following carboplatin treatment 
We previously showed upregulation of both RAD6A and RAD6B genes and RAD6 
protein levels in ovarian tumors and tumor cell lines compared to normal ovarian tissues 
and cells16. In isogenic chemoresistant and sensitive OC cells, RAD6 levels correlated 
with chemoresistance and ability to form spheroids (a stemness trait). Therefore, we 
hypothesized that upregulated RAD6 promotes survival of ovarian tumor cells through 
increased DNA repair and acquisition of a cancer stem cell (CSC) phenotype. To 
examine whether RAD6 status affects expression of stem cell genes and 
characteristics, OV90 cells were transfected with control or RAD6-specific siRNAs, 
treated with carboplatin and CSC and DNA damage response (DDR) protein levels 
were analyzed. Since both the proteins known to have overlapping functions in DNA 
repair, we transfected with siRNAs that target both the RAD6 genes (siRAD6A and 
siRAD6B) and designated as siRAD6. Consistent with previous studies, carboplatin 
treatment increased expression and monoubiquitination of DDR proteins FANCD2, 
PCNA, RAD18 and γH2AX (Fig 1A). However, RAD6 downregulation attenuated 
monoubiquitination of these proteins, both basally and in carboplatin-treated cells (Fig 
1A). Carboplatin treatment increased levels of pro-stemness transcription factor β-
catenin as well as ALDH1A1 and SOX2, and RAD6 depletion significantly diminished 
expression of these proteins, both basally and in response to carboplatin (Fig 1B,C). 
RAD6 has previously been shown to promote stability of β-catenin14 and work with 
RNF20/40 to regulate gene transcription by ubiquitination of H2B10,11,22. Consistent with 
these findings, the levels of ubiquitinated H2B increased along with RAD6 in 
carboplatin-treated cells and decreased in RAD6-downregulated cells (Fig 1B and C). 
The decrease in expression of stemness factors in RAD6-depleted cells was 
accompanied by decreased anchorage-independent growth, as measured by number of 
stem cell spheroids (Fig 1D). To rule out any off-target effects of siRNAs we evaluated 
two siRNAs targeting RAD6B and one siRNA targeting RAD6A and all caused decrease 
in ALDHI1A1 and SOX2 protein levels (Fig 1E). These results suggest that upregulated 
RAD6 activates DDR by monoubiquitination of FANCD2, PCNA and γH2AX and 
regulates stability of β-catenin and expression of CSC genes by ubiquitination of H2B. 
Combined this data suggest RAD6-driven increases in DNA repair and CSC signaling 
promotes chemoresistance and stemness phenotype , two factors that contribute to 
treatment relapse and disease recurrence in ovarian cancer patients1,2. 
RAD6 promotes CSC gene expression by H2B monoubiquitination-mediated 
epigenetic changes 
Similar to the protein levels, analysis of SOX2 and ALDH1A1 transcript levels showed 
over 50% decrease in RAD6-depleted OV90 cells compared to RAD6 proficient cells,  in 
both untreated and in response to carboplatin exposure (Fig 2A and B), indicating 
upregulated RAD6 stimulates CSC gene expression. RAD6 is known to stimulate gene 
transcription through the monoubiquitination of histone H2B at lysine 120 (H2B-Ub), 
which promotes downstream H3K4 and H3K79 methylation (forming H3K4me3 and 
H3K79me3)23–25. These modified histones promote and maintain open chromatin 
conformation allowing enhanced gene transcription within that region26–28. In order to 
confirm that increased RAD6 stimulates expression of these genes by chromatin 
modification, chromatin immunoprecipitation (ChIP) assays were performed in SKOV3 
cells to detect changes in levels of H2B-Ub within the promoter region of ALDH1A1 and 
SOX2. RAD6B depletion by siRNA substantially reduced levels of H2B-Ub in both 
promoters, while there was no change within the β-actin promoter, which is not 
regulated by RAD6 and served as the negative control (Fig 2C). As β-catenin stability 
and nuclear localization are regulated by RAD6B (Fig S1)14,29, the promoters for 
ALDH1A1, and SOX2 were analyzed for putative β-catenin/TCF binding sites. Two 
consensus sites [CTTTG(A/T)(A/T)]30 were identified in the ALDH1A1 promoter (on 
coding strand) and one in SOX2 (on non-coding strand). SKOV3 cells (transfected with 
control or RAD6B siRNA) were treated with carboplatin (2.5 µM, 8 hours) to stimulate 
expression of these genes and ChIP was performed on the regions containing these 
potential β-catenin binding sites. The putative β-catenin/TCF binding site nearest the 
ALDH1A1 start codon (284-290 bp upstream of the ATG) was pulled down and the 
signal intensity decreased in siRAD6B-treated cells (Figure 2D) while the distal site in 
the ALDH1A1 promoter (833-839 bp upstream of start codon) and the putative site in 
the SOX2 promoter (651-657 bp upstream of the ATG) had no detectable β-catenin 
ChIP signal (data not shown). As expected, there was no detectable β-catenin bound to 
the β-actin promoter (negative control). Interestingly, the β-catenin binding site seen to 
be actively regulated in this study was previously shown to bind β-catenin in ovarian 
cancer mammospheres31. To further evaluate the possibility that chemotherapy-induced 
stress promotes CSC phenotype in OC by upregulated RAD6-mediated ubiquitin 
signaling, SKOV3 cells were passaged in the presence of low levels of carboplatin (2.5 
µM). Continuous exposure to sub-lethal concentration of carboplatin progressively 
increased the level of RAD6 with each passage (Fig 2E). As predicted, H2B-Ub levels 
increased, as did expression of CSC proteins SOX2, ALDH1A1 and β-catenin in 
response to carboplatin treatment. RAD6B has previously been shown to stabilize β-
catenin and increase its nuclear localization in breast epithelial cells14. Consistently, 
RAD6 knockdown also affected β-catenin protein levels and its nuclear localization in 
OC cells (Fig S1). SKOV3 cells were systematically exposed to increasing 
concentrations of carboplatin to generate carboplatin resistant cells. We previously 
showed that RAD6 protein levels correlated with increased resistance to carboplatin 
(from 0 to 20μM)16 and this correlates with ability to form stem cell spheres (Fig 2F) 
indicating a link between chemoresistance, stemness and expression of RAD6.  
Chemotherapy induces RAD6 expression and stem cell signaling genes in 
ovarian tumors and poor prognosis in OC patients 
The previous results indicate a connection between chemotherapy-induced upregulation 
of RAD6 and acquired chemoresistance and stemness in OC cells through RAD6-
mediated ubiquitin signaling, resulting in increased DDR and expression of CSC 
proteins (Fig 1A-C and 2). In order to determine if these findings translate to the clinical 
setting, a small pilot study was conducted with 26 OC patients. The expression of 
RAD6B was measured in matched tumor samples collected before and after the 
patients received standard carboplatin/taxane chemotherapy. RAD6B expression 
increased by an average of 4.9 fold (p<0.01) in tumor specimens collected after 
chemotherapy compared to their matched pre-chemo samples (Fig 3A and B). 
Moreover, increased RAD6B expression correlated with poor progression free survival 
(PFS) in these patients (Fig 3C). Statistically there was no difference in RAD6 levels 
based on the debulking status (p= 0.23).  Interestingly, when stratifying patients by 
mean cut point of 5.0 (<= 5.0 vs. >= 5.1), higher levels of RAD6 correlated to the 
recurrence rates 37.5 vs. 70% (p=0.01), respectively. Consistent with the in vitro data, 
expression of CSC markers ALDH1A1 and SOX2 were also increased in response to 
carboplatin chemotherapy by 2.7 (p<0.05) and 2.6 (p<0.05) fold, respectively (Fig 3A 
and B). The changes in RAD6B, ALDH1A1 and SOX2 transcript levels from individual 
patients are given in figure S2. To further confirm the mRNA results, pre- and post-
chemotherapy tumor samples were analyzed by immunohistochemistry (IHC) for RAD6 
and SOX2 protein levels. Due to the limited tumor samples collected, especially post-
chemotherapy samples, the number of proteins that can be analyzed was restricted. 
Consistent with the mRNA levels, IHC staining showed significant increase in the 
expression of RAD6 and SOX2 in tumor samples collected after chemotherapy 
compared to the tumors collected before chemotherapy (Fig 3D, E and S3).  These 
results combined with DDR and CSC expression data strongly implicate RAD6 in 
chemoresistance and poor patient outcomes. The findings are in agreement with 
previous studies showing that RAD6B levels are increased in breast cancer and 
correlate with chemoresistance and decreased survival12,13,32.  
Inhibition of RAD6 using a small molecule inhibitor (SMI) TZ9 induces DNA 
replication stress, decreased DNA repair and a CSC phenotype  
 To test whether pharmacological inhibition of RAD6 can attenuate its ubiquitination 
signaling mediated acquired chemoresistance and stemness in OC cells, we examined 
TZ9 [4-Amino-6-(phenylamino)-[1,3,5]triazin-2-yl)methyl-4-nitrobenzoate], a previously 
identified RAD6-specific inhibitor (Fig 4A)33,34. Exposure of OV90 cells to TZ9 induced 
γH2AX foci, a marker of DNA double strand breaks (DSB) and stalled replication forks 
(Fig 4B). Consistent with RAD6 downregulation by siRNA, TZ9 treatment reversed 
activation of DDR in response to carboplatin as evidenced by decreased ubiquitination 
of FANCD2, PCNA and γH2AX (Fig 4C). Additionally, TZ9 treatment in OV90 cells for 
24 or 48 hours results in accumulation of cells in S and G2 phases compared to DMSO 
treated cells (Fig 4D and E). These proteins represent activation of multiple pathways 
as PCNA ubiquitination indicates translesion synthesis and FANCD2 is a member of the 
Fanconi anemia tumor suppressor and homologous recombination repair pathways, 
suggesting that RAD6 inhibition could sensitize cells to DNA damaging 
chemotherapeutic agents such as carboplatin. Furthermore, TZ9 treatment significantly 
decreased invasiveness of both isogenic platinum-sensitive (A2780) and resistant 
(A2780/CP70) cells in matrigel (Fig 4F) suggesting that RAD6 inhibition could reduce 
aggressiveness of ovarian tumors.  
The increase in γH2AX in RAD6 knockdown or inhibited cells suggests replication 
stress. This is supported by the substantial co-localization of γH2AX foci with regions of 
active DNA replication, as determined by EdU incorporation (Fig 5A). Consistently, 
depletion (siRNA) or inhibition (TZ9) of RAD6 significantly diminished clonogenic 
survival in OC cells (Fig 5B). Moreover, treatment of RAD6 downregulated cells with 
TZ9 did not show any additional effects over siRNA, suggesting TZ9-mediated effects 
are specific for RAD6. To further examine replication dynamics in RAD6-deficient cells, 
single cell DNA fiber analysis was conducted in SKOV3 cells as outlined in figure 5C. 
Treating cells with either TZ9 or knocking down RAD6 significantly attenuated 
replication fork velocities compared to control siRNA treated cells (Fig 5E). As expected, 
carboplatin treated cells showed increased stalled/collapsed/terminal forks compared to 
control cells (Fig 5D, F and S4). Similarly, TZ9 or RAD6 knockdown cells also exhibited 
increased stalled/terminal forks. Consistent with the attenuated PCNA and FANCD2 
ubiquitination, combination of carboplatin and RAD6 deficiency (siRNAs or TZ9) 
resulted in several fold increase in stalled/terminal forks (Fig 5F). These findings 
indicate that increased RAD6 levels protect OC cells from replication stress, likely 
through promoting expression of DDR and DDT proteins.  
Similar to RAD6 deficiency, TZ9 treatment caused loss of pro-transcription histone 
modifications H2B-Ub and H3K79me3 as well as expression of CSC genes ALDH1A1 
and SOX2 both basally and in response to carboplatin (Fig 6A- C). ALDH1A1 has been 
strongly linked to stem cell characteristics in multiple normal and cancer cell lines 
including ovarian35–37. This loss of CSC gene expression was accompanied by a 
substantial decrease in their ability to form tumor spheres. TZ9 inhibited both number 
and size of the spheroids in a dose-dependent manner in OV90 (Fig 6D and E) and 
SKOV3 (Fig S5A and B) cells.  
RAD6 SMI sensitizes OC cells to carboplatin treatment 
Collectively, these studies indicate RAD6 inhibition impairs DDR as well as CSC 
signaling, suggesting that RAD6 inhibition may sensitize cancer cells to DNA damaging 
chemotherapeutic agents, like carboplatin. To evaluate this, multiple OC cell lines were 
tested in clonogenic survival assays using various concentrations of TZ9 and 
carboplatin. First, we determined the concentration-dependent responses for both TZ9 
and carboplatin in all cell lines used (Fig 7, S5C-D and data not shown)16,33,35. Both TZ9 
and carboplatin alone cause varying degrees of OC cell death; however, the 
combination with TZ9 caused significantly increased sensitivity to carboplatin in all OC 
cell lines tested (Fig 7 and S5C and D). Analysis of different concentrations of the drug 
combinations revealed 4µM carboplatin and 50µM TZ9 as the most effective conditions 
in all the OC cell lines tested (Fig 7C). These findings are consistent with a study in 
breast cancer cells, where a RAD6 inhibitor induced apoptosis and enhanced lethality of 
the platinum drug cisplatin38. Together these data conclusively demonstrate that RAD6 
SMI significantly sensitizes OC cells to carboplatin, a drug that is typically used to treat 
OC patients. Furthermore, our studies suggest RAD6 could be an effective therapeutic 
target to prevent and treat acquired chemoresistance and disease recurrence in OC, the 
main factors contributing to the low survival rate of these patients. Moreover, normal 
tissues including ovarian express low levels of RAD6; therefore, it is likely that RAD6 
inhibitors would selectively target the RAD6 overexpressing cancer cells, as was seen 
in breast cancer16,38. To test this, normal immortalized fallopian tube epithelial and 
ovarian surface epithelial cell lines (FTEC and IOSE80, respectively) and OC cell lines 
(SKOV3, OV90 and A2780) were evaluated in growth inhibition assays using different 
concentrations of TZ9 (Fig S6). The OC cell lines were significantly more sensitive to 
RAD6 inhibition than the normal ovarian cells, suggesting RAD6 inhibitors may have 
less toxic effects to normal cells and tissues. 
Discussion 
RAD6 levels are increased in melanoma, breast and ovarian cancers13,15,16,39. Both 
RAD6 proteins promoted cellular proliferation and invasion in normal human liver cells 
and RAD6B is associated with tumorigenesis and platinum resistance in breast12,13,32 
and ovarian16 cancer. Though initial treatment is typically quite successful in OC 
patients, tumor recurrence is extremely high in this disease and frequently accompanied 
by acquired chemoresistance causing poor survival among these patients1,2. One 
mechanism cancer cells use to evade chemotherapy is altered regulation of DDR and 
repair mechanisms4–6,40. RAD6 is well known as a DNA repair protein and was initially 
identified in yeast as a key component of DNA repair pathways, where it functions with 
RAD18 in allowing replication to bypass bulky DNA lesions and in DSB repair7. RAD6 
and RAD18 regulate DNA polymerase switching during TLS through PCNA 
monoubiquitination41–43. RAD6-mediated histone modification is vital for efficient DNA 
repair and damage tolerance44,45. Furthermore, increased levels of these proteins 
provide resistance to chemotherapeutic drugs that impact DNA replication, such as 
platinum drugs like carboplatin and cisplatin, as higher levels of RAD18 enhance TLS 
and DSB repair by monoubiquitination of PCNA and FANCD2 respectively46–48. 
Consistent with this we have shown that knocking down or inhibiting RAD6 in OC cells 
triggered replication stress (Fig 4B-E and 5) and decreased activation of DNA repair 
and damage tolerance pathways in response to carboplatin treatment (Fig 1A and 4C). 
Recent work with RAD6 SMI in breast cancer cells showed that they cause PARP-1 
activation and apoptosis supporting RAD6 as an effective target for treating multiple 
neoplasms38. Therefore, treating OC tumors with a RAD6 inhibitor could be an effective 
new treatment strategy to counter acquired chemoresistance.  
The CSC hypothesis states that recurrent tumors are largely due to a small population 
of cancer cells that dedifferentiated as CSCs. CSCs have properties which allow them 
to evade treatment and proliferating, differentiating back into tumor cells and 
reestablishing tumors once treatment is concluded4–6. Many chemotherapeutic 
strategies currently being developed target CSCs that evade approved treatments. We 
have shown that RAD6B is upregulated in response to carboplatin treatment in OC cells 
and patient tumors where it correlates with poor PFS (Fig 2E and 3) and that increased 
RAD6B levels promote expression of CSC proteins and acquisition of stem cell 
phenotype in OC cell lines (Fig 1B-C and 2)16. Knocking down RAD6 decreased 
expression of CSC proteins and impaired the ability of OC cells to form stem cell 
spheres (Fig 1C and D). These results were recapitulated using RAD6 SMI TZ9 (Fig 6) 
indicating that RAD6 inhibitors may be effective for preventing OC disease recurrence in 
patients. TZ9 alone induced cell death in OC cells and sensitized these cells to 
carboplatin (Fig 5B, 7, and S5) which is frequently utilized in treating OC patients 
indicating that combination therapy may be warranted. There are several RAD6 
inhibitors currently being investigated, though an ideal clinical RAD6 SMI has yet to be 
discovered34,38,49. Thus we have designed a family of RAD6 inhibitors based upon the 
SMI TZ9 and these compounds show promise as they have performed well in in vitro 
RAD6 ubiquitin conjugation activity assays and in blocking RAD6 activity in an array of 
cancer cell lines, including OC33. The LC50 of several of these new SMI are superior to 
that of TZ9 suggesting that they may be more effective and more extensive evaluation 
is being undertaken to determine their efficacy. 
RAD6 is also known to regulate gene transcription through histone modification. RAD6 
partners with RNF20/40 to monoubiquitinate histone H2B at lysine residue 12010,50,51. 
This triggers further histone modification, including H3K4me3 and H3K79me3, and 
together these modified histones promote an open chromatin structure that allows gene 
transcription26,52,53. H2B monoubiquitination is required for efficient differentiation of 
embryonic stem cells54, and this mechanism is likely to be active in CSCs as well. There 
are increased H2B-Ub and H3K79me3 levels in response to carboplatin treatment (Fig 
1B and C) or overexpression of RAD6B16 and knocking down or inhibiting RAD6B 
decreases these modifications (Fig 1B, 1C and 6A). Western blot and ChIP analysis 
confirm that H2B-Ub levels increase in response to carboplatin and decrease within the 
promoters of two CSC genes, ALDH1A1 and SOX2, when the cells are depleted of 
RAD6B (Fig 2C). Loss of RAD6B also resulted in decreased β-catenin binding to the 
ALDH1A1 gene promoter (Fig 2D). Therefore, it appears that RAD6 is also promoting 
CSC protein levels by both the WNT/β-catenin pathway and histone modification and 
chromatin rearrangement, suggesting that RAD6 inhibition would be more effective than 
chemotherapeutic agents that target WNT signaling alone.  
RAD6B increases the levels of multiple proteins that have been proposed as potential 
targets for treating various types of cancer, including β-catenin, SOX2 and ALDH1A1 
making it a very attractive target as multiple cancer-associated proteins will be 
simultaneously impacted. β-catenin is a transcription factor and effector of the WNT 
signaling pathway which is highly conserved and essential for regulating developmental 
processes and stemness55–58. It is likely that RAD6B promotes CSC gene expression 
both by H2B ubiquitination and stabilization of β-catenin14,54,59. ALDH1A1 regulates 
normal stem cell proliferation and is frequently overexpressed in cancers and is a 
prominent member of ALDH protein family that is associated with resistance to radiation 
and chemotherapy and stemness. We have previously shown that ALDH1A1 is an 
important marker for OC stem cell phenotype and chemoresistance and cells 
expressing high levels of ALDH1A1 display increased migration and invasion 
potential35. Furthermore, ALDH1A1 has been reported as a direct target of ȕ-catenin in 
ovarian cancer and ȕ-catenin regulated ALDH1A1 is critical for the maintenance of 
ovarian tumorspheres31. SOX2 is a transcription factor regulating expression of genes 
involved in chromatin remodeling, RNA scaffolding, pluripotency, proliferation, cell 
migration, cell invasion, transcription, and maintenance of stemness60. Importantly, 
reciprocal regulation of ALDH1A1 and SOX2 has been demonstrated in ovarian cancer 
and impacts CSC proliferation and tumor progression61. Our findings suggest that novel 
treatment regimens utilizing RAD6 SMI in combination with existing frontline 
chemotherapeutic drugs such as carboplatin would be an effective therapeutic strategy. 
This report shows that inhibiting RAD6B decreases DNA repair and damage tolerance 
mechanisms, causing replication stress and DNA damage. The RAD6 SMI TZ9 
increased sensitivity to carboplatin, strongly suggesting that this combination could be 
effective at reducing acquired chemoresistance and protecting against disease 
recurrence (Fig 8). This would represent a significant improvement in treating patients 
with this deadly disease. Furthermore, RAD6B expression is relatively low in normal 
cells and thus RAD6 inhibitors would likely cause little damage to surrounding normal 
tissue and combination therapy typically allows reduced levels of each 
chemotherapeutic agent further reducing side effects associated with high doses of 
these drugs. 
Materials and methods 
Cell lines, culture methods and reagents 
The OV90 and SKOV3 cells used in this study were acquired from ATCC and isogenic 
A2780 and A2780/CP70 cell lines were described previously35. Carboplatin-resistant 
SKOV3 cells were generated and utilized previously16.  FTEC cells were a kind gift from 
Dr. Amir Jazaeri62. Commercially available cell lines utilized in this study were either 
validated or acquired in summer 2015. OV90 and SKOV3 cells were cultured in 1:1 
DMEM/F12 (Corning, Manassas, VA) and A2780 and A2780/CP70 cells in RPMI 
(Corning). Cell lines were routinely tested for Mycoplasma contamination. All media 
were supplemented with 10% FBS (Atlanta Biologicals, Flowery Branch, GA) and 1x 
Penicillin/Streptomycin (Mediatech/Corning). The RAD6 SMI, TZ9, was synthesized 
according to methods described previously34,63. Carboplatin and other chemicals unless 
specified otherwise were purchased from Sigma (St Louis, MO). Multiple siRNAs were 
utilized for this work to confirm results and include RAD6A: 5’-
GAACAAGCUGGCGUGAUUdTdT-3’64, RAD6B-1: 5’-
CAAACGAGAAUAUGAGAAAdTdT-3’64, and RAD6B-2: 5'-
UUUCUCAUAUUCUCGUUUGdTdT-3'. All siRNAs were purchased from Dharmacon 
(Lafayette, CO) and transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) 
according to the manufacturer’s instructions. Combination of RAD6A and RAD6B 
siRNAs (denoted siRAD6) were used for all experiments except figures 1C and 1D, 
where only RAD6B siRNA used. For this work, the following antibodies specific to these 
proteins were utilized: ALDH1A1 (sc-22589), β-catenin (sc-1496), FANCD2 (sc-20022), 
GAPDH (sc-32233), PCNA (sc-56), RAD18 (sc-52949) (Santa Cruz Biotechnology, 
Santa Cruz, CA); RAD6 (Bethyl Laboratories, Montgomery, TX); H2B (18977), 
H3K79me3 (2621), SOX2 (97959) (Abcam, Cambridge, MA); Ub-PCNA (13439) (Cell 
Signaling, Danvers, MA); γ-H2AX (05-636), H2B-Ub (51312) (Millipore, Billerica, MA).  
Western blotting 
Protein isolation and Western blots were performed as described previously65. Briefly, 
cells were washed thrice with ice-cold PBS and lysed in ice-cold cytoskeletal buffer 
[CSK: (10 mM PIPES (pH 6.8), 100 mM NaCl, 300 mM sucrose, 3 mM MgCl2, 1 mM 
EGTA, 1 mM dithiothreitol, 0.1 mM ATP, 1 mM Na3VO4, 10 mM NaF and 0.1% Triton 
X-100)] freshly supplemented with protease and phosphatase inhibitors (Roche, 
Indianapolis, IN). Protein concentrations were quantified using Bradford assay (Bio-Rad, 
Hercules, CA), and samples were normalized for equal loading. Samples were 
denatured by addition of 6x Laemmli buffer and heated at 100 °C for 15 minutes and 
resolved by SDS-PAGE and desired proteins identified by immunoblotting using specific 
antibodies. 
Clonogenic Survival Assays 
Cells were counted, and 500 cells were seeded per well in six well culture dishes. The 
following day, cells were treated with DMSO (vehicle control) or the indicated doses of 
carboplatin or TZ9. After twenty-four hours, cells were washed thrice with PBS and 
twice with growth medium. Colonies were allowed to form in complete growth medium 
for 10 days. After 10 days, colonies were fixed with methanol, stained with crystal violet 
(0.5% w/v) and counted as described previously66.   
Cell Cycle Analysis 
Cells were plated at 50% confluency in appropriate growth medium and allowed to 
attach overnight. The following day, cells were treated with the indicated concentrations 
of TZ9 or DMSO (vehicle control) for 24 hours. Cells were trypsinized, washed thrice 
with ice-cold PBS, and stained with PI solution (40 ug/ml Propidium Iodide in PBS, 10 
ug/ml RNase A) at 37°C for 30 min and analyzed using a BD FACSCanto II (BD 
Biosciences, San Jose, CA).  
Chromatin immunoprecipitation (ChIP) 
SKOV3 cells transfected with control or RAD6B-specific siRNAs were grown for 48 
hours after transfection and chromatin was isolated and subjected to ChIP using the 
Simple ChIP Enymatic Plus Kit following manufacturer’s suggested protocol (Cell 
Signaling). Rabbit IgG supplied with the kit was utilized as a negative control and 
chromatin containing monoubiquitinated H2B was immunoprecipitated using Ubiquityl-
Histone H2B (Lys120) (D11) XP Rabbit mAb (Cell Signaling #5546) and chromatin 
bound to β-Catenin was immunoprecipitated with anti-β-Catenin antibody (Bethyl 
#A302-010A). Promoter regions (defined as 1000 bp upstream of the ATG) for 
ALDH1A1 (AY338497.1), SOX2 (NG_009080.1), and ACTB (β-actin, NG_007992.1, 
negative control) were analyzed for putative β-catenin/TCF binding sites using 
MatInspector (Genomatix, Munich, Germany). Consensus β-catenin/TCF 
[CTTTG(A/T)(A/T)] binding sites were identified in promoters of ALDH1A1 (2 sites 290-
284 and 839-833 bases upstream of the ATG) and SOX2 (657-651 bases upstream of 
ATG). As anticipated no sites were detected in the β-actin gene promoter region. For the 
β-catenin ChIP, SKOV3 cells were treated with 2.5 µM carboplatin for 8 hours to 
stimulate expression of β-catenin, SOX2 and ALDH1A1. PCR was used to detect 
precipitated promoter regions as follows: ALDH1A1 (243 to 418 bp before ATG - 
forward: 5’-CTCTGATTCCAAGTCTGTCAG and reverse: 5’-
CCAGTGCTCCAGCATCGAATT and 705 to 904 bp before ATG - forward: 5’-
ATTGTCCTTCAGCTAAATATTA and reverse 5’- GCCAGCAGGACTTTTAGGGA) and 
SOX2 (542 to 778 bp upstream of ATG -  forward: 5’-CCCTGCACCAAAAAGTAAATC 
and reverse: 5’-CCGGGTTTTGCATGAAAGG) and β-actin (607 to 851 bp upstream of 
ATG - forward: 5’-GCCAGGTAAGCCCGGCCA and reverse: 5’-
GCCCGGCTCAGACAAAGA) was used as a control.  
DNA Fiber Assay 
SKOV3 cells were either treated with RAD6 siRNA for 48 hours or TZ9 (60µM) 
overnight followed by carboplatin (20µM) for 4 hours. Cells were then pulsed with 25µM 
CldU for 30 min (Invitrogen) followed by 30 min labeling with 250µM IdU (Invitrogen). 
Cells were trypsinized and re-suspended in ice cold PBS, and a small drop of cell 
suspension placed on glass slide and lysed for 5 minutes with 8µl of lysis buffer (0.5% 
SDS, 200 mMTris-HCl pH 7.4, 50 mM EDTA). DNA fibers were stretched by tilting 
slides to a 15° angle and air dried, fixed in 3:1 methanol:acetic acid, denatured in 2.5M 
HCL and blocked with 5% BSA. Next slides were incubated with rat anti-CldU and 
mouse anti-IdU for one hour followed by sheep anti-mouse Cy3 and goat anti-rat Alexa 
Fluor 488. To calculate fork velocity, the length of each replication region was measured 
and multiplied by DNA extension factor (2.59kbp/µm). This gives the DNA length in 
base pairs that was synthesized in 30 min labeling of CldU followed by 30 min labeling 
of IdU. Dividing the DNA length (kb) by 60 minutes will give the fork velocity achieved 
for a minute. For fork velocity, 100 replication fibers were measured and statistical 
significance were assessed using Mann-Whitney test and students “t” test was 
performed using Prism 5 (GraphPad Software, La Jolla, CA). To measure 
stalled/collapsed/terminal forks, a total of 100 replication structures (both red and green) 
from above experiment, red only tracks were counted and presented as stalled 
replication fork. The experiments were repeated thrice and mean values were presented 
with statistical significance. 
Sphere formation assays  
OV90 and SKOV3 cells were harvested in log phase, counted, and seeded in ultra-low 
attachment 6 well dishes (VWR, Radnor, PA) at 1000 to 10,000 cells/well. The cells 
were allowed to grow and form spheres as detailed earlier16. In brief, cells were carefully 
dispersed as single cells, cultured in stem cell-specific serum free media [2 mL; 1:1 
DMEM/F-12 supplemented with 1x penicillin/streptomycin, B27 and N2 supplements 
(Gibco, Waltham, MA), and growth factors [recombinant human epidermal growth factor 
(EGF) and fibroblast growth factor (FGF), both from Invitrogen] in an ultra-low 
attachment six well plates for 10-12 days. After seeding the cells were observed daily to 
ensure that spheres were forming. Fresh media containing growth supplements EGF 
(20 ng/ml) and FGF (20 ng/ml) was added every 72 h. Spheres containing ≥50 cells 
were scored as large (true stem cell spheres), while spheres <50 cells were considered 
to be small spheres. 
Immunohistochemistry 
Ovarian tumor tissues collected before and after chemotherapy were stained for the 
expression of RAD6 and SOX2 proteins by immunohistochemistry. Antigen retrieval 
was carried out by heating the tissue specimens in 10mM sodium citrate buffer, pH 6.0. 
Endogenous peroxidase activity was inhibited by incubating the sections in 3% 
hydrogen peroxidase for 10 min. Tissue sections were incubated with specific primary 
antibodies, followed by a specific biotinylated secondary antibody, and then conjugated 
HRP streptavidin and DAB (3,3'-Diaminobenzidine) chromogen (Vector Laboratories, 
Burlingame, CA) and tissues were counterstained with hematoxylin (Vector 
Laboratories). Stained sections were analyzed by Zeiss Axioscope 2 microscope and 
images captured by AxioCam camera. DAB intensity was analyzed by Fiji Image J 
software. This process was carried out without any knowledge of the identity of each 
tissue sample to prevent bias in scoring the samples. 
Tumor samples and RNA Isolation  
A small pilot study was conducted with 26 advanced stage III/IV epithelial OC patients. 
After approval from the University of South Alabama Institutional Review Board, written 
consent from patients was obtained for acquisition of tumor during the surgical 
management of their disease.  Tumor samples were collected at time of diagnosis 
(referred to as pre-chemo) using diagnostic laparoscopy, as well as during debulking 
surgery following 3 cycles of platinum / taxane based neoadjuvant chemotherapy 
(referred to as post-chemo). In order to provide adequate molecular data, all patients 
had at least 1 cubic centimeter of excess tumor tissue for analysis. Those without 
adequate tumor were not included in this analysis. Paraffin was removed from tumor 
samples and samples were lysed overnight. Total RNA was isolated from formalin-fixed, 
paraffin-embedded (FFPE) tissue samples by Trizol following manufacturer’s protocol 
(Invitrogen). Purity and quantity of total RNA in samples were determined using a 
NanoDrop ND-1000 UV spectrophotometer (NanoDrop, Wilmington, DE).  
RT-PCR 
Total RNA from adherent ovarian cancer cells and dispersed sphere cells was isolated 
by Trizol following manufacturer’s protocol (Invitrogen).  Tumor sample RNA was 
prepared as outlined above. cDNA was prepared from total RNA using cDNA 
preparation kit (Applied Biosystems, Foster City, CA). Gene-specific primers (Prime 
PCR; Bio-Rad) were used for semi-quantitative RT-PCR analysis with 2μl cDNA in a 
total volume of 20μl using the following protocol: initial denaturation for 5min at 94°C; 30 
cycles of denaturation for 30s at 94°C, annealing for 30s at 65°C and extension for 30s 
at 72°C; and final extension for 5min at 72°C.  
Immunofluorescence (IF) staining  
For immunofluorescence, cells were seeded in triplicate into 35mm glass bottom culture 
dishes (FluoroDish – World Precision Instruments, Sarasota, FL) for 48 hours. Next 
cells were treated with CPT or vehicle control (DMSO) as indicated and fixed with 4% 
formaldehyde at room temperature for 10 minutes and then in cold (−20°C) 100% 
methanol for 10 minutes. Fixed cells were then blocked in 10% goat serum for 30-60 
minutes and washed 3 times with PBS. Cells were subsequently incubated overnight at 
4°C with primary antibodies in PBS containing 5% BSA as described previously66. Cells 
were washed three or four times with PBS supplemented with 1% BSA and incubated 
with appropriate fluorophore-conjugated secondary antibody (IgG-Cy3, IgG-FITC or 
IgG-Cy5 – Invitrogen) for 2h at room temperature. Detection of protein foci was done 
using the Nikon Ti Eclipse confocal microscope (Nikon) and images were acquired at 
100x and as described previously66. 
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Figure Legends 
Figure 1: RAD6 promotes expression of CSC proteins and acquisition of stemness 
phenotype and is important for efficient DDR. Control and siRAD6 transfected OV90 
cells were treated with 20 µM carboplatin and DDR and CSC proteins were assessed by 
Western blot. RAD6 knockdown impairs carboplatin induced DDR (A & B) and 
decreases pro-transcription histone modifications H2B-Ub and H3K79me3 and 
expression of CSC signaling proteins (B & C). The results presented are representative 
blots and the average values obtained from three independent experiments with each 
band adjusted to the corresponding GAPDH control. (D) Consistent with the expression 
studies, knocking down RAD6 impaired the ability of OV90 cells to form stem cell 
spheres by anchorage-independent growth, as both number and size of number of 
spheroids decreased. Left panel shows 1 view field of a representative stem cell sphere 
culture and the right panel is total spheroid count from multiple experiments. (E) Multiple 
siRNAs targeting either RAD6A or RAD6B were used to ensure the impact was not 
siRNA specific and to confirm that regulation occurs through both RAD6 isoforms. Left 
panel is a representative blot and the right is a compilation of 3 experiments. *p<0.05 
and **p<0.01.  
 
Figure 2: Carboplatin treatment induces expression of RAD6 and RAD6 subsequently 
regulates ALDH1A1 and SOX2 through pro-transcription histone modifications. (A) To 
determine if RAD6 regulates CSC gene expression, OV90 cells transfected with control 
siRNA or siRAD6B-1 and treated with carboplatin or vehicle (DMSO) were used for 
qRT-PCR. Knockdown of RAD6B decreased both basal and carboplatin-induced 
expression of (A) SOX2 and (B) ALDH1A1. (C) ChIP was used in SKOV3 cells to 
determine if depletion of RAD6 (siRAD6B-1) altered the level of pro-transcription H2B-
Ub in the promoters of ALDH1A1 (243 to 418 bp upstream of ATG) and SOX2 (542 TO 
778 bp before ATG) genes. The ȕ-actin is not regulated by RAD6 and was used as a 
negative control. (D) ChIP for β-catenin binding to putative binding sites 
([CTTTG(A/T)(A/T)] located in same regions analyzed for H2B-Ub in C). RAD6B 
depletion (siRNA) reduces β-catenin interaction at a putative β-catenin/TCF binding site 
located at 284-290 bp upstream of the ALDH1A1 ATG. There are no putative β-catenin 
binding sites in the β-actin promoter thus it was used as a negative control. (E) 
Systematic exposure of SKOV3 cells to sub-lethal carboplatin (2.5µM) caused 
progressive increase in RAD6 and associated H2B-Ub levels as well as expression of 
RAD18 and CSC proteins. (F) Ability to grow as stem cell spheres increased with 
acquired carboplatin resistance indicating correlation between stemness and 
chemoresistance. *p<0.05, **p<0.01 and ***p<0.001. 
Figure 3: Expression of RAD6, ALDH1A1 and SOX2 increase in OC patient tumors in 
response to chemotherapy and RAD6 expression correlates with progression free 
survival. A small pilot study was conducted with 26 advanced stage III/IV epithelial OC 
patients. Tumor samples were taken from OC patients (n=26) prior to chemotherapy 
(carboplatin/Taxane; designated pre-chemo) and following chemotherapy (post-chemo) 
and gene expression analyzed and compared. (A) The post-chemo samples showed 
increased expression of RAD6B, ALDH1A1 and SOX2 compared to the matched pre-
chemo sample from the same patient. (B) The mean fold increase for the 3 genes in all 
matched patient samples. (C) RAD6 expression correlated with poor PFS in OC 
patients. High RAD6 was considered anything over 5 fold and PFS study was 
conducted for 2 years. Inset table shows the number of cases present at different time 
points in the two groups. (D and E) IHC staining of post-chemo samples showed 
increased expression of RAD6 and SOX2 compared to the matched pre-chemo sample 
form the same patient.  ***p<0.001. 
 
Figure 4: RAD6 SMI TZ9 impairs activation of DNA damage response to carboplatin 
and induces replication stress in OV90 cells. (A) Structure of the RAD6 SMI TZ9. (B) 
TZ9 causes ȖH2AX foci formation indicating that it causes DNA double strand breaks 
and (C) blocks carboplatin-induced monoubiquitination of FANCD2, PCNA, and ȖH2AX. 
(D and E) OV90 cells treated with TZ9 (10μM) for 24 or 48 hours were tested for cell 
cycle profile. TZ9 causes G2/M cell cycle arrest indicating the presence of DNA damage 
and activation of damage checkpoint. (F) Matrigel invasion assay in isogenic sensitive 
(A2780) and chemoresistant (A2780/CP70) cells showed that the RAD6 inhibitor 
decreased their ability for invasion, suggesting RAD6 may be a valid target for treatment 
of OC. *p<0.05. 
Figure 5: Knocking down or inhibiting RAD6 causes replication stress and decreases 
viability in OC cells. (A). Sites of active DNA replication was labeled using EdU and 
sites of DSB identified by visualizing ȖH2AX foci in RAD6-depleted SKOV3 cells. Many 
of the ȖH2AX foci co-localize with active DNA replication (EdU foci) indicating loss of 
RAD6 in tumor cells leads to replication stress. (B) Small molecule inhibitor (TZ9) of 
RAD6 specifically inhibits clonogenic potential of SKOV3 cells expressing RAD6. 
Downregulation of RAD6 does not show any additional toxic effects by TZ9. (C) Single 
cell DNA fiber analysis was used to assess DNA replication fork dynamics. To measure 
fork velocity, SKOV3 cells were treated with control siRNA or siRAD6B-1 for 48 hours or 
TZ9 (60µM) for overnight and labeled for 30 min with 25 µM CldU followed by 30 min 
labeling with 250 µM IdU as indicated. (D) Representative DNA fiber images for the 
control siRNA or carbo treated samples. (E) The length of fibers was measured in 300 
individual fiber structures from three independent experiments and their fork velocity is 
represented with S.E. (F) To measure stalled forks, SKOV3 cells were treated with 
control siRNA or siRAD6B-1 for 48 hours or TZ9 overnight and then treated with DMSO 
or carboplatin for 4 hours. RAD6 inhibited (siRAD6B-1 or TZ9) cells that are exposed to 
carboplatin showed increased stalled replication fork (red only) compared to the control 
cells.  *p<0.05, **p<0.01 and ***p<0.001.  
Figure 6: RAD6 inhibition with TZ9 prevents RAD6-induced expression of ALDH1A1 
and SOX2 and stemness. (A) OV90 cells were treated with vehicle control or 
carboplatin to induce expression of RAD6 and with the RAD6 inhibitor TZ9. TZ9 
prevented RAD6-induced histone modification and CSC gene expression both basally 
and in carboplatin treated cells. To determine if TZ9 blocks transcription of (B) 
ALDH1A1 and (C) SOX2, qRT-PCR was done on mRNA isolated TZ9 treated and 
control OV90 cells. The levels of both mRNAs were reduced. RAD6 inhibitor TZ9 
decreased stem cell sphere-forming ability in OV90 cells in a dose-dependent manner. 
(D) Representative image and (E) compiled data from 3 experiments. *p<0.05 and 
**p<0.01. 
Figure 7: TZ9 sensitizes OC cells to carboplatin treatment. Clonogenic survival assays 
were conducted using a range of concentrations of the RAD6 SMI TZ9 (0-125µM) and 
carboplatin (0-4 µM) in multiple OC cells lines. Both OV90 (A) and SKOV3 (B) showed 
significant sensitization to carboplatin treatment at multiple concentrations of TZ9. 
Isogenic A2780 and A2780/CP70 cell lines are shown in figure S1. (C) Histogram 
showing compiled data from multiple experiments at the best combination of drugs 
(50µM TZ9 and 4µM carboplatin). *p<0.05, **p<0.01 and ***p<0.001. 
Figure 8: Model showing possible mechanisms by which RAD6-mediated ubiquitin 
signaling regulates acquired chemoresistance and stemness contributing to OC 
recurrence. RAD6 promotes expression of cancer stem cell genes by histone H2B 
ubiquitination and subsequent chromatin remodeling, as well as by enhancing activity of 
pro-stemness transcription factors like ȕ-catenin. RAD6 protects OC cells from DNA 
damage caused by chemotherapy by activating multiple repair and damage tolerance 
pathways including TLS (PCNA-Ub) and FA/homologous recombination (FANCD2-Ub). 
The RAD6-mediated increase in stemness and DNA repair and damage tolerance allow 
some of the tumor cells to evade treatment and re-establish the tumor. 
 
 
Supplemental Figures 
 
Figure S1: RAD6 promotes ȕ-catenin stability and nuclear localization. SKOV3/CP20 
cells treated with control and RAD6 siRNAs and analyzed for ȕ-catenin levels by 
immunofluorescence (A). The average cytoplasmic and nuclear intensities presented 
from multiple experiments (B). TZ9 does not alter RAD6 expression. Western blot for 
OV90 cells treated with the RAD6 SMI TZ9. This drug blocks the catalytic site of RAD6 
but does not impact its expression. Levels of the pro-stemness transcription factor ȕ-
catenin and pro-transcription H2B-Ub were both decreased in TZ9 treated cells, 
suggesting RAD6 regulates CSC marker expression through both pathways (C). 
*p<0.05 and **p<0.01. 
 
Figure S2: The mRNA expression of RAD6 (A), SOX2 (B) and ALDH1A1 (C) in 
individual patients before and after chemotherapy. mRNA expression levels before 
chemotherapy is normalized to 1 in all the patients.  
 
Figure S3: IHC staining intensity of RAD6 (A) and SOX2 (B) in individual patients before 
and after chemotherapy. IHC staining intensity levels before chemotherapy is 
normalized to 1 in all the patients. Several patient samples were unavailable at the time 
of IHC analysis (#26 for RAD6 and 18, 24, and 26 for SOX2). N/A indicates sample was 
unavailable at time of analysis. 
 
Figure S4: Representative DNA fiber images for the siControl, siRAD6 and TZ9 treated 
cells with or without carboplatin. 
 
Figure S5: TZ9 treatment caused a dose-dependent decrease in stem cell sphere 
formation in SKOV3 cells indicating that RAD6 inhibition blocks stemness. (A) is a 
representative image and (B) is average from 3 experiments.  *p<0.05 and **p<0.01. 
TZ9 sensitizes OC cells to carboplatin treatment. Clonogenic survival assays were 
conducted using a range of concentrations of the RAD6 SMI TZ9 (0-125µM) and 
carboplatin (0-4µM) in isogenic sensitive (C) A2780 and resistant (D) A2780/CP70 cells 
lines.  
 
Figure S6: TZ9 toxicity effects are specific to OC cells (SKOV3, OV90, A2780), 
compared to normal immortalized fallopian tube epithelial (FTEC) and ovarian surface 
epithelial cells (IOSE80) in MTS assays. 














